Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Krystal Biotech Inc (KRYS)

Krystal Biotech Inc (KRYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,346,294
  • Shares Outstanding, K 29,232
  • Annual Sales, $ 389,130 K
  • Annual Income, $ 204,830 K
  • EBIT $ 161 M
  • EBITDA $ 168 M
  • 60-Month Beta 0.49
  • Price/Sales 19.16
  • Price/Cash Flow 34.98
  • Price/Book 6.06

Options Overview Details

View History
  • Implied Volatility 50.08% (+2.91%)
  • Historical Volatility 41.36%
  • IV Percentile 68%
  • IV Rank 38.99%
  • IV High 73.25% on 04/08/25
  • IV Low 35.27% on 12/05/25
  • Expected Move (DTE 7) 11.08 (4.48%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 562
  • Volume Avg (30-Day) 551
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 5,240
  • Open Int (30-Day) 4,810
  • Expected Range 236.18 to 258.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.42
  • Number of Estimates 3
  • High Estimate 1.62
  • Low Estimate 1.30
  • Prior Year 1.20
  • Growth Rate Est. (year over year) +18.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
244.50 +1.13%
on 03/12/26
298.30 -17.11%
on 02/17/26
-29.19 (-10.56%)
since 02/13/26
3-Month
231.68 +6.72%
on 12/18/25
298.30 -17.11%
on 02/17/26
+2.61 (+1.07%)
since 12/12/25
52-Week
122.80 +101.35%
on 05/23/25
298.30 -17.11%
on 02/17/26
+69.89 (+39.40%)
since 03/13/25

Most Recent Stories

More News
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference

PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference...

KRYS : 247.26 (-1.61%)
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment...

KRYS : 247.26 (-1.61%)
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results...

KRYS : 247.26 (-1.61%)
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

PITTSBURGH, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted Regenerative...

KRYS : 247.26 (-1.61%)
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH,...

KRYS : 247.26 (-1.61%)
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis

Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespective...

KRYS : 247.26 (-1.61%)
Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis

PITTSBURGH, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that it will host an investor conference call and webcast tomorrow, Thursday,...

KRYS : 247.26 (-1.61%)
Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference

PITTSBURGH, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 44 th Annual J.P. Morgan Healthcare...

KRYS : 247.26 (-1.61%)
Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

PITTSBURGH, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 8 th Annual Evercore Healthcare Conference...

KRYS : 247.26 (-1.61%)
Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results

$97.8 million in 3Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in 4Q Updated U.S. VYJUVEK label expands eligible...

KRYS : 247.26 (-1.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

See More

Key Turning Points

3rd Resistance Point 264.76
2nd Resistance Point 261.06
1st Resistance Point 254.16
Last Price 247.26
1st Support Level 243.56
2nd Support Level 239.86
3rd Support Level 232.96

See More

52-Week High 298.30
Last Price 247.26
Fibonacci 61.8% 231.26
Fibonacci 50% 210.55
Fibonacci 38.2% 189.84
52-Week Low 122.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar